−33,203.5215 EUR
−32.91 M EUR
291.31 K EUR
About NEOVACS NOM. EO 1,-
Sector
Industry
CEO
Hugo Brugière
Website
Headquarters
Suresnes
Founded
1992
ISIN
FR0014010856
Neovacs SA is a biotechnology company focused on therapeutic vaccines targeting the treatment of autoimmune diseases. The firm is developing a product portfolio using its Kinoid technology through self-antigens, which cause autoimmune or inflammatory diseases. Its product portfolio includes IFNa kinoid, IL-4/13 kinoid, and IgE kinoid. The company was founded by Daniel Zagury on April 16, 1993 and is headquartered in Paris, France.
Related stocks
Frequently Asked Questions
The current price of A41BPL is 1.1750 EUR — it has decreased by −3.85% in the past 24 hours. Watch Neovacs SA stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LS exchange Neovacs SA stocks are traded under the ticker A41BPL.
A41BPL stock has fallen by −6.75% compared to the previous week, the month change is a −6.75% fall, over the last year Neovacs SA has showed a −6.75% decrease.
A41BPL reached its all-time high on Jul 24, 2025 with the price of 1.3000 EUR, and its all-time low was 1.2220 EUR and was reached on Jul 24, 2025. View more price dynamics on A41BPL chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
A41BPL stock is 4.00% volatile and has beta coefficient of 1.27. Track Neovacs SA stock price on the chart and check out the list of the most volatile stocks — is Neovacs SA there?
Yes, you can track Neovacs SA financials in yearly and quarterly reports right on TradingView.
A41BPL net income for the last half-year is −1.92 M EUR, while the previous report showed −30.99 M EUR of net income which accounts for 93.79% change. Track more Neovacs SA financial stats to get the full picture.
No, A41BPL doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Neovacs SA EBITDA is −6.57 M EUR, and current EBITDA margin is −2.26 K%. See more stats in Neovacs SA financial statements.
Like other stocks, A41BPL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Neovacs SA stock right from TradingView charts — choose your broker and connect to your account.